Ji-Lai Bian, Mei-Mei Wang, En-Juan Tong, Jing Sun, Ming Li, Department of Medical Oncology, The Fifth People's Hospital of Dalian, Dalian 116021, Liaoning Province, China.
World J Gastroenterol. 2017 Jun 21;23(23):4311-4316. doi: 10.3748/wjg.v23.i23.4311.
Intrahepatic cholangiocarcinoma (ICC) is a relatively rare form of liver cancer with a poor prognosis. The therapeutic options for patients with advanced ICC are limited and usually ineffective. There is currently no approved targeted therapy for ICC, although accumulating evidence supports inhibition of the PI3K/Akt/mTOR signaling pathway as a promising therapeutic strategy in the treatment of ICC. Here, we report a patient with stage IV ICC harboring a mutation who responded well to the mTOR inhibitor everolimus. Computed tomography and magnetic resonance imaging demonstrated shrinkage of the tumor and maintenance of a partial response for 6.5 mo after everolimus treatment as the best response. To the best of our knowledge, this is the first clinical case report in the literature of clinical benefit from everolimus treatment in an ICC patient with mutation.
肝内胆管癌（ICC）是一种相对罕见的肝癌，预后较差。晚期 ICC 患者的治疗选择有限，通常效果不佳。目前尚无针对 ICC 的批准靶向治疗药物，尽管越来越多的证据支持抑制 PI3K/Akt/mTOR 信号通路作为治疗 ICC 的一种有前途的治疗策略。在这里，我们报告了一名患有 IV 期 ICC 的患者，该患者携带 突变，对 mTOR 抑制剂依维莫司反应良好。计算机断层扫描和磁共振成像显示，在依维莫司治疗后 6.5 个月，肿瘤缩小，部分缓解得到维持，这是最佳反应。据我们所知，这是文献中首例关于依维莫司治疗 突变 ICC 患者的临床获益的临床病例报告。
